All posts

HS GovTech has a 150 per cent upside, says Echelon

Echelon Capital Markets analyst Mike Stevens maintained a “Speculative Buy” rating and C$0.80 per share target price on HS GovTech Solutions (HS GovTech Solutions Stock Quote, Charts, News, Analysts, Financials CSE:HS) in an update to clients on Thursday. Stevens said he’s encouraged by the company’s operational momentum as well as its recently reported cost savings.

HS GovTech, which develops and sells information and communication management systems for health inspection departments of federal, provincial, state and municipal governments in Canada and the US, provided a business update on Thursday, saying it’s had a strong start to the new year. 

On the company’s payments solution HSPay, its total processed volume (TPV) has so far in 2023 exceeded all of 2022’s TPV, and HS GovTech has on-boarded six new agencies since the start of the year with another six pending deployment over the last weeks of the first quarter.

The company said its realized cost saving achieved so far in 2023 amounts to an annualized $1 million and that it’s also seeing an increase in contracts executing through sole source procurement instead of the traditional Request for Proposal route, arguing that the change shows the strength and reach of the company’s platform.

“The regulatory agency market is continuing to increase the pace of procurements, especially when contrasted against the previous three years during the pandemic. Our business development team is attending a record number of conferences; a number of which we are delighted to be giving the keynote addresses at,” said CEO Silas Garrison in a press release.

HS GovTech also recently closed on an overnight marketed public offering and non-brokered private placement for gross proceeds of about $2.5 million, issuing about 6.8 million units comprised of one common share and one warrant entitling holders to one common share at an exercise price of $0.50 for a period of 36 months.

Commenting on the news, Stevens said he’s very encouraged by the impressive operational updates as well as the reported cost savings, while on the capital raise, he said although raising debt might have been the previously presumed route, the recent rise in the HS shares made an expedited equity offering a more realistic option.

“We are maintaining our previous price target of C$0.80 and Speculative Buy rating. We believe the capital raise, while dilutive, will help to remove any potential near-term funding overhangs attributed to the Company’s shares,” Stevens wrote.

“Our DCF is based on a 14 per cent discount rate and 8.5x EV/EBITDA terminal valuation multiple – both of which we view as relatively conservative and subject to revision with operational execution,” he said.

By the numbers, Stevens is estimating full 2022 revenue and EBITDA of $6.1 million and negative $3.8 million, respectively, which moves to 2023 revenue and EBITDA of $9.5 million and negative $1.7 million, respectively.

Stevens’ projected return to target at the time of publication was 150.0 per cent.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: hs
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago